Dr. Ankur Parikh, D.O
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $307,962 | 70 | 87.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $33,345 | 13 | 9.5% |
| Unspecified | $4,810 | 5 | 1.4% |
| Travel and Lodging | $2,541 | 8 | 0.7% |
| Food and Beverage | $1,923 | 33 | 0.5% |
| Education | $89.00 | 1 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Foundation Medicine, Inc. | $340,991 | 92 | $0 (2023) |
| F. Hoffmann-La Roche AG | $4,546 | 4 | $0 (2022) |
| Bayer Healthcare Pharmaceuticals Inc. | $3,060 | 3 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $817.72 | 10 | $0 (2019) |
| Eli Lilly and Company | $264.40 | 1 | $0 (2019) |
| Boston Scientific Corporation | $144.37 | 1 | $0 (2024) |
| Sirtex Medical Inc | $137.02 | 1 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $135.62 | 7 | $0 (2020) |
| Tempus AI, Inc | $122.32 | 1 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $111.59 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $332.75 | 3 | Boston Scientific Corporation ($144.37) |
| 2023 | $34,114 | 17 | Foundation Medicine, Inc. ($33,345) |
| 2022 | $59,762 | 16 | Foundation Medicine, Inc. ($55,217) |
| 2021 | $77,915 | 15 | Foundation Medicine, Inc. ($76,250) |
| 2020 | $119,436 | 26 | Foundation Medicine, Inc. ($119,397) |
| 2019 | $42,109 | 30 | Foundation Medicine, Inc. ($40,121) |
| 2018 | $13,785 | 13 | Foundation Medicine, Inc. ($13,613) |
| 2017 | $3,217 | 10 | Foundation Medicine, Inc. ($3,050) |
All Payment Transactions
130 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/30/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $66.06 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 09/25/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $122.32 | General |
| Category: NONE | ||||||
| 07/30/2024 | Boston Scientific Corporation | TheraSphere Y90 Glass Microspheres 10 GBq (Device) | Food and Beverage | In-kind items and services | $144.37 | General |
| Category: TheraSphere_PI | ||||||
| 12/19/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 12/08/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 11/22/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 10/24/2023 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug) | Consulting Fee | Cash or cash equivalent | $657.00 | General |
| Category: Oncology | ||||||
| 10/16/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 09/12/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 08/25/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,680.00 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 06/13/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $585.00 | General |
| Category: Oncology | ||||||
| 05/17/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,095.00 | General |
| Category: Oncology | ||||||
| 05/03/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $37.01 | General |
| Category: OPHTHALMOLOGY | ||||||
| 04/13/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 04/05/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $34.46 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/08/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,680.00 | General |
| Category: Oncology | ||||||
| 02/20/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $585.00 | General |
| Category: Oncology | ||||||
| 02/14/2023 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 02/08/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $40.12 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,164.67 | Research |
| Study: PAN-TUMOR LANDSCAPE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1-4 GENOMIC ALTERATIONS | ||||||
| 12/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $981.13 | Research |
| Study: CO-MUTATIONAL LANDSCAPE OF KEY FIBROBLAST GROWTH FACTOR RECEPTOR FGFR ALTERATIONS IN INTRA-HEPATIC CHOLANGIOCARCINOMA ICCA, BLADDER CANCER BC AND GLIOMA | ||||||
| 12/28/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $5,674.50 | General |
| Category: ONCOLOGY | ||||||
| 12/28/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $877.50 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2022 | Foundation Medicine, Inc. | FOUNDATIONONE CDX (Device) | Consulting Fee | Cash or cash equivalent | $1,579.50 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PAN-TUMOR GENOMIC ALTERATION LANDSCAPE OF FGFR1-4 | F. Hoffmann-La Roche AG | $1,908 | 1 |
| PAN-TUMOR LANDSCAPE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1-4 GENOMIC ALTERATIONS | F. Hoffmann-La Roche AG | $1,165 | 1 |
| CO-MUTATIONAL LANDSCAPE OF KEY FIBROBLAST GROWTH FACTOR RECEPTOR FGFR ALTERATIONS IN INTRA-HEPATIC CHOLANGIOCARCINOMA ICCA, BLADDER CANCER BC AND GLIOMA | F. Hoffmann-La Roche AG | $981.13 | 1 |
| CO-MUTATIONAL LANDSCAPE OF KEY FIBROBLAST GROWTH FACTOR RECEPTOR FGFR ALTERATIONS IN INTRA-HEPATIC CHOLANGIOCARCINOMA ICCA, BLADDER CANCER BC, GLIOMA | F. Hoffmann-La Roche AG | $491.53 | 1 |
| RANDOMIZED STUDY OF AM0010 IN COMBINATION WITH FOLFOX COMPARED TO FOLFOX ALONE AS SECOND-LINE TX IN PTS WITH META PANCREATIC CANCER THAT HAS PROGRESSED DURING OR FOLLOWING A FIRST-LINE GEMCITABINE CONTAINING REGIMEN | Eli Lilly and Company | $264.40 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 249 | 444 | $121,717 | $39,105 |
| 2022 | 7 | 220 | 408 | $103,715 | $36,663 |
| 2021 | 3 | 110 | 179 | $88,014 | $18,763 |
| 2020 | 6 | 281 | 561 | $241,495 | $36,628 |
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 55 | 226 | $62,150 | $16,604 | 26.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 36 | 49 | $17,150 | $5,475 | 31.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 51 | 52 | $12,702 | $5,415 | 42.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 35 | 35 | $14,875 | $4,848 | 32.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 43 | 52 | $6,760 | $3,309 | 48.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 14 | $5,040 | $1,991 | 39.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 16 | $3,040 | $1,464 | 48.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 50 | 201 | $52,715 | $17,308 | 32.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 34 | 34 | $13,925 | $5,040 | 36.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 35 | 37 | $8,990 | $4,210 | 46.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 20 | 26 | $8,650 | $3,286 | 38.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 37 | 60 | $10,180 | $3,238 | 31.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 33 | 39 | $5,070 | $2,281 | 45.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $4,185 | $1,301 | 31.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 57 | 93 | $55,242 | $10,595 | 19.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 22 | 52 | $21,892 | $3,588 | 16.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 19 | 19 | $7,325 | $3,132 | 42.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 12 | 15 | $3,555 | $1,449 | 40.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 98 | 233 | $98,093 | $14,450 | 14.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 57 | 104 | $61,776 | $9,629 | 15.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 70 | 168 | $45,864 | $6,673 | 14.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 29 | 29 | $26,216 | $3,908 | 14.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 12 | 12 | $8,316 | $1,297 | 15.6% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 15 | 15 | $1,230 | $669.91 | 54.5% |
About Dr. Ankur Parikh, D.O
Dr. Ankur Parikh, D.O is a Student in an Organized Health Care Education/Training Program healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2008. The National Provider Identifier (NPI) number assigned to this provider is 1245499144.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ankur Parikh, D.O has received a total of $350,670 in payments from pharmaceutical and medical device companies, with $332.75 received in 2024. These payments were reported across 130 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($307,962).
As a Medicare-enrolled provider, Parikh has provided services to 860 Medicare beneficiaries, totaling 1,592 services with total Medicare billing of $131,159. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Hematology & Oncology
- Location Philadelphia, PA
- Active Since 06/05/2008
- Last Updated 02/05/2013
- Taxonomy Code 390200000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1245499144
Products in Payments
- FOUNDATIONONE CDX (Device) $204,062
- FOUNDATIONONE LIQUID (Device) $127,986
- FOUNDATIONACT (Device) $8,870
- Vitrakvi (Drug) $2,300
- MK-7339 (Drug) $817.72
- Stivarga (Drug) $760.00
- TheraSphere Y90 Glass Microspheres 10 GBq (Device) $144.37
- SIR-Spheres Microspheres (Device) $137.02
- XT CDX (Device) $122.32
- EYLEA (Biological) $111.59
- XOSPATA (Drug) $105.58
- OPDIVO (Biological) $91.09
- XTANDI (Drug) $89.00
- FOUNDATIONONE (Device) $73.69
- YUTIQ (Drug) $66.06
- BRAFTOVI (Drug) $22.36
- EMPLICITI (Biological) $21.82
- Xermelo (Drug) $21.74
- Smoflipid (Drug) $16.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Philadelphia
Christopher Melnic, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $219,429
Dr. Abdallahsassine Geara, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $130,717
Edward Kreider, Md, Phd, MD, PHD
Student in an Organized Health Care Education/Training Program — Payments: $80,580
Julia Crowley, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $74,775
Katie Walsh
Student in an Organized Health Care Education/Training Program — Payments: $66,680
Lizamarie Bachier-Rodriguez, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $63,584